Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This is the perfect spot for bottom fishing. Through in your line to land the big one!
This stock has .02 written all over it!!
Bumped up to HOD at .0064. It should move up to .007 in the AM.
Look at the chart, still at rock bottom!
Great Opportunity to start a position in this stock!
UGA will be publicizing the results. That should be the best source because they are the ones involved in the research. That’s good enough for me!
Look at the bright side. Fewer employees cost less. No need to pay for a lot of employees when UGA is doing all the weightlifting. They have money set aside to do the trials. Not to mention them at UGA has connections to a lot of investors who would probably love to get their hands on this company. They arranged an $8B deal with an investor a few years back and the University did very well on that deal. A good researcher doesn’t pursue a boondoggle. The researcher at UGA has outstanding credentials This stock will be rewarding to those who are willing to wait! JMHO!
I agree and believe all these three tests , in vitro, culture and mice are already underway. They don’t need to conduct these tests sequentially.
They will likely announce the results very soon and if all goes as expected, human trials will be fast tracked. This could very well be the miracle America has been waiting for!
At UGA the lead molecule developed by SBFM is being studied to see how effective it is in attacking PLpro, a papain like protease, which is a main component of viruses, SARS COVID-2 the causative agent of COVID 19. PLpro is responsible for the replication of the virus molecule. The test involves three stages: in vitro study, cell culture studies and mice studies. If proven successful in neutralizing PL pro, UGA will submit its findings to the FDA to begin human trials for the development of a vaccine.
Only 80 million outstanding shares and a 30 million share float, people should be jumping all over this stock. If the interest in this stock grows with its low float, it’s value will grow quickly! JMHO!
This stock is ready to rocket. Imagine the heights where this stock could go with a volume of 10 million. With a 300,000 share transaction the ask moved from .01 to .0155, a 55% gain. I think this stock which was once at .55 can easily move to .05 or .10 with increased volume. I will be starting a position in this stock on Monday morning.
His endorsement of Kamala Harris is probably the reason the stock tanked yesterday!
Stock purchaser’s exceeded sellers in yesterday’s action!
If it blows past .0213 today, it’s off to the races and it will easily move into the .03’s. Get ready for lift off!
UGA also sold an orphan drug developed in their lab to an investor for $8.4B to an investor back in 2015!
Just hoping the “one two punch” doesn’t turn into a “sucker punch!”
Covid 19 Treatment Cycle Options:
Contract Disease
Get Symptoms
Go To Hospital
Get Admitted
Get Treatment
Symptoms Gone
Go Home
or
Contract Disease
Get Symptoms
Use RLF-100 Inhaler
Symptoms Gone
Go To Work
My preference: Option 2
Hopefully, we will see a paradigm shift away from vaccines as a preventative to therapeutics as a cure. With emphasis placed on therapeutics, the emphasis on vaccines will be relegated to second place. Great News for holders of RLFTF! God Bless America!
Is a paradigm shift beginning to occur in the pharmaceutical world? Maybe with the President’s emphasis on therapeutics, greater focus will be placed on bio-pharmaceuticals and their value in the marketplace will increase. Expect many Big Pharma Companies will be turning their attention to the biopharmaceuticals and their science. This is a great time to be a holder of a therapeutic stock. IMHO!
Let’s hope among all the treatment drugs he is taking, one of them is RLF-100
The president and First Lady test positive for COVID. They need to take RLF-100 immediately!
When Trump talks about COVID-19, he always says: “soon we’re going to have many new vaccines for covid-19 and “therapeutics!” He does recognize the role therapeutics will play in the battle of COVID-19 and RLF-100 just happens to be the most effective drug out their in stopping the progression of this disease in those infected.
That’s exactly why the manufacturing and distribution channels have been established! Pure and Simple! Yesterday was just a move to grab money off the table. Nothing more, nothing less. All the sellers yesterday will be buying back in today.
I have knowledge of a person who has hantavirus which affects the lungs. This person has been hospitalized for two months and has yet to recover. Has RLFTF ever successfully treated a patient with hantavirus?
This person has the virus and pneumonia. It’s a disease spread by rodents and only two out of three people who contract the disease survive.
This may be a good day for buyers
TD Ameritrade: Bid: .018. Ask: .0242
Still Early though!
RLFTF moving on up again after large profit taking sell off in the Swiss market. Over 18 million trades. A lot of interest in this one. The fireworks are about to begin. All we need is a match to set this thing into orbit!
Relief Therapeutics Holding SA (OTCMKTS: RLFTF) is heating up fast on a surge of volume and is heading upwards again after several weeks of choppy waters. Relief Therapeutics is quickly emerging as among the most exciting stories in small caps as its coronavirus therapeutic RLF-100 (aviptadil) gains serious traction. The Company recently raised approximately USD $36 million which will be used primarily to fund the ongoing Fast Track FDA trial of RLF-100 (aviptadil) in coronavirus acute respiratory distress syndrome (NCT04311697) as well as to run a phase 3 study in Europe.
RLFTF took off in the last week of July after the FDA granted expanded access protocol for treatment of Respiratory Failure in COVID-19 with RLF-100. Aviptadil is the first coronavirus therapeutic to demonstrate the ability to block replication of the virus in human lung cells and monocytes, while at the same time preventing synthesis of cytokines in the lungs. Aviptadil has been granted FDA Fast Track Designation and emergency use IND authorization and is showing excellent results with a number of coronavirus patients showing significant recoveries after several days of treatment.
Relief Therapeutics Holding SA (OTCMKTS: RLFTF) operating out of Switzerland aims to become a key player in the biotechnology and pharmaceutical industry. The Company provides patients with therapeutic relief from diseases for which high needs persist. Relief believes in effectively treating patients while its investors realize significant return on investment. The Company is focused on late stage clinical assets and strives to reduce development times and costs to quickly reach high quality decision-enabling results.
Relieve lead compound is RLF-100 (aviptadil) currently in advanced clinical development to treat severe COVID-19 patients. The Company has initiated a Phase IIb/III study in Acute Respiratory Distress Syndrome induced by COVID-19: in July 2020, Data Safety Monitoring Board interim safety/futility analysis of 30 patients recommended study continue as planned. In August 2020, promising results reported from the first 21 patients treated with RLF-100 under FDA Expanded Access Protocol authorization. Topline results expected in early-4th quarter 2020. The FDA has granted Emergency Use Investigational New Drug (“IND”) authorization and Expanded Access Protocol authorization granted for treatment of respiratory failure in COVID-19. Fast track designation granted by FDA for acute lung injury/ARDS associated with COVID-19. FDA IND granted to test inhaled formulation in patients with moderate and severe COVID-19 to prevent progression to respiratory failure
RLFTF
In the first half of 2020 Relief appointed Dr. Gilles Della Corte as Chief Medical Officer. The Company also hired Virtuoso Sarl, a strategic and tactical operational and trial delivery services firm, as Clinical Trials Manager to set up and run RLF-100 clinical trials in Europe. Relief successfully upgraded from US OTC Pink to OTCQB, meeting all qualifications and raised $34.4 million via its Share Subscription Facility in July and August.
Raghuram (Ram) Selvaraju, Chairman of the Board of Relief, commented: “With the onset of COVID-19, the Relief team immediately recognized that, based on its multimodal mechanism of action, RLF-100 has a high potential to become a life-saving treatment for severe COVID-19 patients with acute lung injury. We rapidly started clinical development in the US, and I am excited about the strong progress already made in the past few months to advance this important program. The Company is fully financed to successfully complete the two US COVID-19 trials underway and is now preparing for European trials with RLF-100.”
RLF-100 is believed to be the first COVID-19 therapeutic to demonstrate the ability to block replication of the SARS-CoV-2 virus in human lung cells and monocytes, while also preventing synthesis of cytokines in the lung. Since July 2020, severe COVID-19 patients have been treated with RLF-100 under U.S. FDA Emergency Use Investigational New Drug (IND) authorization and Expanded Access Protocol authorization for the treatment of respiratory failure in COVID-19. According to a recent Reuters article: “Relief Therapeutics sees 60-70% chance of COVID-19 drug approval” Relief Therapeutics’ chairman said he was optimistic its RLF-100 (aviptadil) drug will win approval for treating COVID-19 patients in a matter of months. The Swiss group owns the rights to the drug in the United States and Europe. Its U.S. partner NeuroRx is running multicentre clinical trials here, including a Phase IIb/III trial in patients who are severely ill because of the consequences of COVID-19, the respiratory disease caused by the new coronavirus.
RLFTF is heating up and running northbound again after several weeks of choppy waters. Relief Therapeutics is quickly emerging as among the most exciting stories in small caps as its coronavirus therapeutic RLF-100 (aviptadil) gains serious traction. The Company recently raised approximately USD $36 million which will be used primarily to fund the ongoing Fast Track FDA trial of RLF-100 (aviptadil) in coronavirus acute respiratory distress syndrome (NCT04311697) as well as to run a phase 3 study in Europe. RLFTF took off in the last week of July after the FDA granted expanded access protocol for treatment of Respiratory Failure in COVID-19 with RLF-100. Aviptadil is the first coronavirus therapeutic to demonstrate the ability to block replication of the virus in human lung cells and monocytes, while at the same time preventing synthesis of cytokines in the lungs. Aviptadil has been granted FDA Fast Track Designation and emergency use IND authorization and is showing excellent results with a number of coronavirus patients showing significant recoveries after several days of treatment. Microcapdaily covers Relief on the regular and first reported on the Company on August 3 as Relief was running northbound off its $0.05 base.
If they have a cure for pancreatic cancer and lung cancer, that will be HUGE! There is no known drug in the marketplace that can cure pancreatic cancer.
Rlf:SW in the green on the Swiss market today. This could be the start of a good week and perhaps some great news. IMHO!
The translation of “uberverkauft” is “oversold!” Author believes this stock at its present price is oversold.
None of the drugs you indicated have a 100% efficacy for seriously ill patients. My dad died if Sepsis. It is a serious blood disease and if the disease persists, it will eventually destroy all the body’s organs.
Perhaps those patients who have not suffered a long term illness who are administered the drugs you mentioned may respond but many do not! There is no “silver bullet” for those who are very ill and contract sepsis!
Tommy was cured of COVID-19 but somehow became infected by Sepsis which is not uncommon for patients with long stays in an ICU.
Sepsis is a life-threatening condition that occurs when an existing infection — such as one that develops in a cut, a respiratory infection, or a urinary tract infection — triggers an immune response that affects the body’s tissues and major organs.
Sepsis constitutes a medical emergency because, if a person does not receive treatment, it can lead to death.
In the United States, over 1 million people experience severe sepsis every year, and up to 30 percent of these individuals die as a result.
Worldwide, over 30 million people have sepsis each year, and up to 6 million people die from it. Most commonly, sepsis is caused by Staphylococcus aureus and Escherichia coli.
His death can not be attributed to the failure of RLF-100 but due to a staff infection which occurred during his stay in the hospital. RLF-100 kills the virus, but there is no drug on the market that can effectively fights staff infection.
My heart and prayers go out to his his family.
Thanks to all his coworkers , the healthcare providers, and the many supporters who tried so hard to save Captain Tommy's life.
This stock will open on the Swiss exchange on Monday because that is not a holiday. It will be interesting to watch that action including their session on Tuesday.
The stocks with the “chatter” are the ones that “matter!”
On the DJI, 70 stocks fell and only two rose. RLFTF fell only 1.56%, not bad for this stock considering the market sell off. We will see RLFTF move up tomorrow. IMHO!
“Nice big white candlestick!”
NeuroRx CEO Javitt should arrange a meeting with McKesson!
Once the distribution channel is in place, it could also be used for the rapid distribution of a “cure therapeutic drug” as well!
Like to see this stock behave like HGEN which went from .50 to $5.50 in a six month period.
Just recovered from a triple bottom. Should move upwards!
RLF only off 1.2% off the high of the day which occurred at the opening. This may close green on the Swiss Exchange. Great News for shareholders who didn’t jump ship!